Thiosulfuric Acid

Thiosulfuric Acid

SCHEMBL727622

N=C(N)N.N=C(N)N.O=S(O)(O)=S

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2

The experimentally established mechanism targets of Thiosulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
BLM P54132 2/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CA5A P35218 2/20 0.40
CA5B Q9Y2D0 2/20 0.40
TSHR P16473 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
NT5E P21589 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiosulfuric Acid SCHEMBL2434380 1.00
Thiosulfuric Acid SCHEMBL28216026 0.85 BLM (0.42) KDM4EBLMCYP2D6CYP2C19NPSR1
Sulfuric Acid SCHEMBL170524 0.84
Sulfuric Acid SCHEMBL28148838 0.84 BLM (0.59) KDM4EBLMCYP2D6CYP2C19NPSR1
Sulfuric Acid SCHEMBL1318239 0.84 BLM (0.59) KDM4EBLMCYP2D6CYP2C19NPSR1
Sulfuric Acid SCHEMBL10539875 0.81 KDM4E (0.50) KDM4EBLMCYP2D6CYP2C19NPSR1
Sulfuric Acid SCHEMBL4167092 0.80 BLM (0.56) KDM4EBLMCYP2D6CYP2C19NPSR1
Sulfuric Acid SCHEMBL4162831 0.80 BLM (0.56) KDM4EBLMCYP2D6CYP2C19NPSR1
Sulfuric Acid SCHEMBL22127325 0.80 BLM (0.56) KDM4EBLMCYP2D6CYP2C19NPSR1
Thiosulfuric Acid SCHEMBL21683091 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12539510-B2 Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge CEPHEID (US) 2026-02-03 US claimed
US-20240141415-A1 INTEGRATED PURIFICATION AND MEASUREMENT OF DNA METHYLATION AND CO-MEASUREMENT OF MUTATIONS AND/OR MRNA EXPRESSION LEVELS IN AN AUTOMATED REACTION CARTRIDGE CEPHEID (US) 2024-05-02 US claimed
EP-3551332-B1 INTEGRATED PURIFICATION AND MEASUREMENT OF DNA METHYLATION AND CO-MEASUREMENT OF MUTATIONS AND/OR MRNA EXPRESSION LEVELS IN AN AUTOMATED REACTION CARTRIDGE CEPHEID (US) 2024-01-10 EP claimed
US-20220226809-A1 INTEGRATED PURIFICATION AND MEASUREMENT OF DNA METHYLATION AND CO-MEASUREMENT OF MUTATIONS AND/OR MRNA EXPRESSION LEVELS IN AN AUTOMATED REACTION CARTRIDGE CEPHEID (US) 2022-07-21 US claimed
JP-4785315-B2 2011-10-05 JP claimed
EP-2049677-B1 METHOD FOR ISOLATING CELLS MERCK PATENT GMBH (DE) 2011-07-20 EP claimed
EP-1254075-B1 NONABORATE COMPOSITIONS AND THEIR PREPARATION UNITED STATES BORAX INC (US) 2007-02-21 EP claimed
EP-1254075-A4 NONABORATE COMPOSITIONS AND THEIR PREPARATION UNITED STATES BORAX INC (US) 2005-07-27 EP claimed
US-6919036-B2 Reacting borate with guanidinium or imidazolidinium compound; heating; crystal structure; forming ceramic; fire retarders, microbiocide U.S. BORAX INC. (US) 2005-07-19 US claimed
JP-2003523964-A 2003-08-12 JP claimed
US-20030109751-A1 Nonaborate compositions and their preparation U.S. BORAX INC. 2003-06-12 US claimed
EP-1254075-A1 NONABORATE COMPOSITIONS AND THEIR PREPARATION U.S. BORAX INC. (US) 2002-11-06 EP claimed
WO-2001053201-A1 NONABORATE COMPOSITIONS AND THEIR PREPARATION U.S. BORAX INC. (US) 2001-07-26 WO claimed
US-12539510-B2 Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge CEPHEID (US) 2026-02-03 US disclosed
US-20240141415-A1 INTEGRATED PURIFICATION AND MEASUREMENT OF DNA METHYLATION AND CO-MEASUREMENT OF MUTATIONS AND/OR MRNA EXPRESSION LEVELS IN AN AUTOMATED REACTION CARTRIDGE CEPHEID (US) 2024-05-02 US disclosed
EP-3551332-B1 INTEGRATED PURIFICATION AND MEASUREMENT OF DNA METHYLATION AND CO-MEASUREMENT OF MUTATIONS AND/OR MRNA EXPRESSION LEVELS IN AN AUTOMATED REACTION CARTRIDGE CEPHEID (US) 2024-01-10 EP disclosed
US-6277970-B1 NUCLEOTIDE AND AMINO ACID SEQUENCE OF GENE INVOLVED IN PRION INFECTION; SCREENING OF INDIVIDUALS; DRUG SCREENING OF MODULATORS; RECOMBINANT EXPRESSION VECTORS AND HOST CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-08-21 US disclosed
WO-2001053201-A1 NONABORATE COMPOSITIONS AND THEIR PREPARATION U.S. BORAX INC. (US) 2001-07-26 WO disclosed
WO-2001032922-A2 METHODS FOR DETECTION OF A TARGET NUCLEIC ACID SEQUENCE STRATAGENE (US) 2001-05-10 WO disclosed
WO-2000068382-A1 PrP-LIKE GENE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539510-B2 Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge DNMT3A, DNMT1, NSUN2 KDM4E 946/4885BLM 416/4885CYP2D6 3075/4885
US-20030109751-A1 Nonaborate compositions and their preparation NONO, BLVRB, BRI3BP KDM4E 851/4885BLM 324/4885CYP2D6 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.